Daily Brief Private Markets: Doctor Anywhere: From Telehealth App to Integrated Regional Provider (Initiation) and more

Executive Summary

• Regional Omnichannel Healthcare Platform: Doctor Anywhere operates a hybrid medical model across five Southeast Asian markets, integrating a digital telemedicine application with a physical network of clinics and specialist centres. The company serves over three million registered users, providing a single touchpoint that bridges virtual consultations with in-person diagnostic care.
• Strong Institutional Capital Support: The company has secured approximately US$176.0m in total funding from top-tier strategic and financial investors, including a US$40.8m Series C extension in late 2023. This capital supports a closed-loop business model that leverages corporate and insurance partnerships for efficient user acquisition while cross-selling higher-margin physical medical services.
• Profitability Inflection From Cost Discipline, Not Growth: FY2025 delivered the company’s first operating profit in four years, at a margin of roughly 1%, achieved through the Vietnam exit, the wind-down of underperforming units and headcount reduction rather than volume expansion. The company remains net loss-making, the physical clinic network continues to carry material fixed costs, and no new primary capital has been raised since December 2023. The central question is whether a margin bought through rationalisation can be sustained and widened once the one-off cost actions are exhausted.

• Regional Neobanking Transition: Kredivo Group has evolved from a standalone digital credit provider into a diversified Southeast Asian financial services conglomerate, anchored by its acquisitions of Krom Bank and Timo. This strategic expansion allows the company to integrate deposit-taking capabilities with its established point-of-sale checkout infrastructure.
• Proprietary Credit Decisioning Engine: The core value driver is an alternative data scoring model that enables instant underwriting for consumers without formal credit histories. Separately, the group is well funded relative to its stage, having raised approximately US$400m in equity through the March 2023 Series D and secured committed debt facilities approaching US$1.0b to fund the loan book, with a further round reported in December 2025.
• Third-Party Licence Dependency: The May 2026 acquisition of Timo gives Kredivo the brand, technology stack, and customer relationships, but not the banking licence, which remains with BVBank under a cooperation agreement. Termination or adverse modification would suspend deposit-taking in Vietnam and require migration to an alternative licensed partner, feasible in principle given Kredivo owns the front end, but disruptive and unproven in practice.

• Colossal Biosciences was valued at approximately $10.2 billion following a $200M Series C in January 2025.
• The company sells through three channels.
• Colossal Biosciences is expanding from de-extinction into species engineering and conservation infrastructure.

• Firehawk Aerospace was valued at approximately $282M following its $55.8M Series C-1 round in January 2025.
• Firehawk Aerospace manufactures 3D-printed thermoplastic propellant, solid rocket motors, hybrid rocket engines, and complete tactical rockets for the U.S. Department of Defense.
• Firehawk Aerospace is expanding from propulsion technology into end-to-end energetics and munitions manufacturing, with growth vectors across high-volume production programs, adjacent munition categories, and allied manufacturing.